Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

doi:10.1200/JCO.2013.50.5669

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2014

Vergote Ignace B, Jimeno Antonio, Joly Florence, Katsaros Dionyssios, Coens Corneel, Despierre Evelyn, Marth Christian, Hall Marcia, Steer Christopher B, Colombo Nicoletta, Lesoin Anne, Casado Antonio, Reinthaller Alexander, Green John, Buck Martin, Ray-Coquard Isabelle, Ferrero Annamaria, Favier Laure, Reed Nick Simon, Curé Hervé, Pujade-Lauraine Eric

Abstract excerpt

PURPOSE: This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. PATIENTS AND METHODS: Eligible patients had high-risk International Federation of Gynecology and Obstetrics stage I or stage II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer and were not selected for EGFR expression. All...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Eruptions

Share to Erlotinib Hydrochloride

Share to Fallopian Tube Neoplasms

Share to Maintenance Chemotherapy

Share to Neoplasms, Glandular and Epithelial

Share to Peritoneal Neoplasms

Share to Platinum Compounds

Source

Open in PubMed

Identifiers

PMID: 24366937
DOI: 10.1200/JCO.2013.50.5669

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.PMID 24366937Read ↗

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.Semantic proximity Read ↗

A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.Semantic proximity Read ↗

Anlotinib maintenance following adjuvant chemotherapy in newly diagnosed stage III–IV patients with epithelial ovarian cancer: a retrospective studySemantic proximity Read ↗

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.Semantic proximity Read ↗

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.Semantic proximity Read ↗

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.Semantic proximity Read ↗

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.Semantic proximity Read ↗

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.